IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4252
Positioning
Market Dominance
Services
Healthcare
$133M
Stanley Vashovsky
DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = DCGO ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$DCGO DocGo Inc. | 34 | 47 | 28 | 13 | - | - | -19.0% | -14.0% | 100.0% | -22.1% | -16.7% | -57.1% | 0.0% | 0.0x | $133M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
DocGo Inc. (DCGO) receives a "Avoid" rating with a composite score of 33.6/100. It ranks #4252 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Stanley Vashovsky
Chief Executive Officer
Labor Force
2,920
47
36
33
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for DCGO
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for DCGO.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 47 | 51 | -4NEUTRAL |
| MOMENTUM | 13 | 8 | +5NEUTRAL |
| VALUATION | 28 | 20 | +8ALPHA |
| INVESTMENT | 36 | 59 | -23DRAG |
| STABILITY | 33 | 25 | +8ALPHA |
| SHORT INT | 35 | 26 | +9ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -19.0% (sector 5.3%)
GM 100% vs sector 60%, OM -22% vs sector 4%
Capital turnover N/A, R&D intensity 4.0%
Rev growth -57%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags DocGo Inc. with an Avoid rating, assigning a composite score of 33.6/100 and 1 out of 5 stars. Ranked #4252 of 7,333 stocks, DCGO falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
With a quality score of 47/100, DCGO shows adequate but unremarkable business quality. The company reports a return on equity of -19.0% (sector avg: 5.3%), gross margins of 100.0% (sector avg: 59.6%), net margins of -16.7% (sector avg: 2.3%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
DCGO registers a value score of just 28/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.30x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
DocGo Inc.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -57.1% vs. a sector average of 7.8% and a return on assets of -14.0% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
DocGo Inc. is experiencing notably weak momentum with a score of just 13/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -57.1% year-over-year, while a beta of 1.12 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
DCGO's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.12 and a debt-to-equity ratio of 0.00x (sector avg: 0.3x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
DocGo Inc.'s short interest score of 35/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include micro-cap liquidity risk. At $133M (micro-cap), DCGO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
DocGo Inc. is a micro-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #4252 of 7,333 overall (42nd percentile). Key comparisons include ROE of -19.0% trailing the 5.3% sector median and operating margins of -22.1% below the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While DCGO currently exhibits a AVOID profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (13) would have the largest impact on the composite score.
ROE 457% BELOW SECTOR MEDIAN
Gross Margin 68% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 729% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate DocGo Inc. (DCGO) as Avoid with a composite score of 33.6/100 at a current price of $0.75. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in quality (47th percentile) and investment (36th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (13th percentile) and value (28th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
DocGo Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.6/100 places it at rank #4252 in our full 7,333-stock universe. At $133M in market capitalization, DocGo Inc. is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -57% combined with momentum at the 13th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 100% (+40.4pp vs sector) narrow to operating margins of -22% (-25.6pp vs sector) and net margins of -16.7%, yielding a gross-to-net conversion rate of -17%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.75, DocGo Inc. is trading at a premium to fundamental value. Our value factor score of 28/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.3x, P/S of 0.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A conservative balance sheet (0% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 33.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -57% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -16.7% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to DocGo Inc.. Key risk factors include current negative profitability (net margin -16.7%), below-average price stability (33th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -16.7%); below-average price stability (33th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 33th percentile and quality factor at the 47th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures; conservative leverage (0% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate DocGo Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-19.0%), negative profitability, weak asset returns (ROA -14.0%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — DocGo Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, DocGo Inc. receives a Avoid rating with a composite score of 33.6/100 (rank #4252 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on DocGo Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign DocGo Inc. a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10.5/20.
The strongest moat sources are margin superiority (10.5/20) and financial resilience (9.5/20). GM 100% vs sector 60%, OM -22% vs sector 4%. Interest coverage N/A. These pillars form the core of DocGo Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (1.4/20) and economic value creation (2.7/20). Capital turnover N/A, R&D intensity 4.0%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect DocGo Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, declining revenues (-57%) that pressure the earnings outlook. The margin cascade from 100% gross to -22% operating to -16.7% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 47th percentile.
The margin profile shows gross margins of 100%, operating margins of -22%, net margins of -16.7%. Return metrics include ROE of -19.0% and ROA of -14.0%. Relative to the Services sector, gross margins are 40.4 percentage points above the sector median of 60%, and ROE of -19.0% compares to a sector median of 5.3%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 0%, revenue growth of -57%. The sector median D/E is 0%, putting DocGo Inc. in a relatively stronger balance sheet position. Overall balance sheet health is adequate for the current business environment.
Weak momentum (13th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.

AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Motion Acquisition (DCGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, February 17, 2026--DocGo Inc. (Nasdaq: DCGO) ("DocGo"), a leading provider of technology-enabled mobile health services, announced today that Lee Bienstock, Chief Executive Officer, will participate in 1x1 meetings at the TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, and will deliver a presentation at 9:10 AM ET on that day. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.
NEW YORK, January 05, 2026--DocGo Inc. (Nasdaq: DCGO) ("DocGo"), a leading provider of technology-enabled mobile health and medical transportation services, announced today that Norm Rosenberg, Chief Financial Officer, will hold a fireside chat at the 28th Annual Needham Growth Conference on Wednesday, January 14th at 1:30 PM Eastern Time, and will be participating in 1x1 meetings at this event. A webcast of the fireside chat will be available on the investor relations section of DocGo’s website

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share. Ascent Solar Technologies shares dipped 50% to $0.1374 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 152% to $0.7242 after the company announced upgrades to its integration with Microsoft Advertising. Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) gained 75% to $1.9698 after the company announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04. Infobird Co., Ltd (NASDAQ: IFBD) surged 45.3% to $6.00. ReTo Eco-Solutions, Inc. (NASDAQ: RETO) gained 45% to $1.67. Meiwu Technology Company Limited (NASDAQ: WNW) shares jumped 36% to $1.37. Nano Labs Ltd (NASDAQ: NA) surged 31.6% to $1.9502. Nano Labs recently filed annual report on Form 20-F for fiscal year 2023. iCoreConnect Inc. (NASDAQ: ICCT) shares jumped 30.8% to $1.4650. iCoreConnect, last month, closed $2,375,000 convertible note financing. Dogness (International) Corporation (NASDAQ: DOGZ) climbed 22.9% to $8.48. NeoVolta Inc. (NASDAQ: NEOV) surged 18% to $2.0826. BioSig Technologies, Inc. (NASDAQ: BSGM) rose 18% to $1.92. Verb Technology Company, Inc. (NASDAQ: VERB) climbed 18% to $0.2099. Jaguar Health, Inc. (NASDAQ: JAGX) gained 16.7% to $0.1050 after the company reported approval for all proposals at its special meeting of stockholders. Murano Global Investments Plc (NASDAQ: MRNO) rose 13.6% to $11.70. Gaucho Group Holdings, Inc. (NASDAQ: VINO) surged ...
Above 50MA
37.18%
Net New Highs
+51081